Abstract: OBJECTIVE To explore the drug treatment and pharmaceutical care of patients with COVID-19. METHODS The 15 patients with COVID-19 were isolated and treated, who were divided into mild type, normal type, severe type and critical type. Antiviral drugs such as recombinant human interferon α-2a, lopinavir/ritonavir tablets, abidol hydrochloride tablets, chloroquine phosphate and ribavirin injection were used, and no more than 3 kinds of antiviral drugs were used. Pharmaceutical care was carried out in the course of drug treatment. Monitor the adverse reactions during treatment and give symptomatic treatment in time. RESULTS By March 5, 2020, 9 patients were cured, 6 patients were treated in hospital, 3 patients’ clinical symptoms and CT were improved, but nucleic acid test was positive, 1 severe patient turned to normal type, 2 critically ill patients changed to severe type. During the treatment, 11 patients had different symptoms and degrees of adverse reactions, the incidence of adverse reactions was 73.33%, 8 patients had digestive system symptoms, 2 patients developed rash with pruritus, 1 patient slightly increased liver enzymes during treatment. According to the classification of the National Adverse Reaction Monitoring Center, 2 cases were new adverse reactions and 9 cases were general adverse reactions. CONCLUSION At present, there is no clinically proven effective treatment for novel coronaviru. Under the limited recommendations of treatment, it is necessary to explore the relevant drug treatment, including drug selection, drug usage and dosage, and drug treatment course. At the same time, adverse reaction monitoring, timely detection and symptomatic treatment are needed to avoid damage caused by drugs.